Summit Therapeutics Inc.
SMMT
$18.22
-$0.69-3.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 399.25% | 2,509.44% | 35.34% | 24.73% | 280.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -14.53% | -- |
| Total Operating Expenses | 301.20% | 1,174.24% | 57.71% | 81.20% | 184.88% |
| Operating Income | -301.20% | -1,174.24% | -57.71% | -81.20% | -184.88% |
| Income Before Tax | -312.05% | -836.84% | -44.72% | -67.37% | -164.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -312.05% | -836.84% | -44.72% | -67.37% | -164.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -312.05% | -836.84% | -44.72% | -67.37% | -164.50% |
| EBIT | -301.20% | -1,174.24% | -57.71% | -81.20% | -184.88% |
| EBITDA | -301.26% | -1,174.73% | -57.75% | -81.29% | -185.23% |
| EPS Basic | -302.84% | -793.08% | -37.64% | -59.00% | -153.77% |
| Normalized Basic EPS | -302.69% | -1,087.28% | -37.73% | -59.20% | -153.40% |
| EPS Diluted | -289.75% | -746.44% | -45.40% | -71.65% | -162.30% |
| Normalized Diluted EPS | -302.69% | -1,087.28% | -37.73% | -59.20% | -153.40% |
| Average Basic Shares Outstanding | 2.31% | 4.90% | 5.17% | 5.27% | 4.14% |
| Average Diluted Shares Outstanding | 2.31% | 4.90% | 5.17% | 5.27% | 4.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |